Researching and developing new drugs can be complex and expensive. Scientists have to conduct years of basic research to understand how new diseases act at a molecular level in the human body and need to screen thousands of different molecular compounds (the basis for many drugs) to assess their safety and efficacy as potential treatments. After they narrow down the pipeline, researchers perform multiple rounds of testing in the laboratory before advancing the most promising drug candidates for further study. In addition, because the manufacturing requirements for these drugs can be highly variable, pharmaceutical companies may also need to build expensive new infrastructure or redesign existing facilities in order to produce them. Moderna is managing these challenges, leveraging the breadth and depth of AWS services to simplify the research and manufacture of a new class of drugs, based on mRNA, to treat a wide range of diseases.
Moderna has invented proprietary technologies and methods that run on AWS to create mRNA constructs that cells recognize as if they were produced in the body. This invention has empowered Moderna to experiment rapidly on virtually any mRNA sequence, easily shifting between research priorities, without investing in new technology. Moderna runs its Drug Design Studio on AWS’s highly scalable compute and storage infrastructure to quickly design mRNA sequences for protein targets. It then uses analytics and machine learning to optimize those sequences for production so that the company’s automated manufacturing platform can successfully convert them into physical mRNA for testing. In addition, by leveraging AmazonRedshift – AWS’s fully managed data warehousing service – Moderna’s scientists and engineers aggregate results from dozens of experiments that are running in parallel and can easily query and share insights to refine their design and production cycle quickly.
Moderna runs all of its SAP S/4HANA workloads on AWS, including manufacturing, accounting, and inventory management, which enables the company to achieve greater efficiency and visibility across its operations. AWS also powers Moderna’s highly automated production facility, which runs AWS IoT services to connect the manufacturing instruments, robotics, and other critical systems that quickly deliver the mRNA constructs for experimentation. Integrating its systems on AWS provides Moderna with the ability to trace its manufacturing process, facilitating industry best practices in its supply chain, manufacturing, and quality control processes. Moderna also used AWS to essentially copy and paste its digital manufacturing model onto its partner’s facilities for technology transfer, giving Moderna rapid access to the additional production capacity it needs to address global demand.
“The science behind mRNA medicines is advancing at a rapid pace, and building Moderna’s technology platform on AWS gives our scientists the insights, agility, and security they need to continue to lead in the industry,” said Stéphane Bancel, Moderna’s chief executive officer. “With AWS, our researchers have the ability to quickly design and execute research experiments and rapidly uncover new insights to get potentially life-saving treatments into production faster. AWS’s breadth and depth of services are supporting our mission to create a new generation of medicines for patients and are instrumental in our quest to develop a vaccine for COVID-19 and other life-threatening diseases.”
“Running on AWS, Moderna has the agility to continuously refine its research, development, and manufacturing,” said Matt Garman, vice president, sales and marketing at AWS. “Moderna is relying on the proven performance and scale of the world’s leading cloud to innovate and develop drug and vaccine candidates on timelines that may have been impossible even just a few years ago.”